Search results for PX-TA1064

Foravirumab Biosimilar – Anti-RV mAb – Research Grade, ProteoGenix, PX-TA1064

Description of Foravirumab Biosimilar - Anti-RV mAb - Research Grade Introduction Foravirumab Biosimilar – Anti-RV mAb – Research Grade is a monoclonal antibody (mAb) that specifically targets and neutralizes the respiratory syncytial virus (RSV). RSV is a common virus that causes respiratory infections in infants, young children, and older adults. Foravirumab Biosimilar is a biosimilar version of the original mAb, with similar structure, activity, and applications. Structure of Foravirumab Biosimilar Foravirumab Biosimilar is a recombinant humanized IgG1 monoclonal antibody, with a molecular weight of approximately 150 kDa. It is composed of two heavy chains and two light chains, connected by disulfide bonds. The heavy chains consist of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains consist of two constant domains (CL and CL1) and one variable domain (VL). The variable domains are responsible for the specificity of the antibody, as they bind to the target antigen. Activity of Foravirumab Biosimilar Foravirumab Biosimilar specifically targets the fusion protein (F protein) of RSV, which is responsible for viral entry into host cells. The F protein is present on the surface of the virus and is essential for viral attachment and fusion with host cells. Foravirumab Biosimilar binds to the F protein, preventing it from interacting with host cells and thereby inhibiting viral entry and replication. In addition to neutralizing RSV, Foravirumab Biosimilar also has the ability to activate the immune system. It can bind to immune cells, such as natural killer cells and macrophages, and trigger an immune response against the virus. This activity of Foravirumab Biosimilar can help in clearing the virus from the body and providing long-term protection against RSV infections. Applications of Foravirumab Biosimilar Foravirumab Biosimilar has multiple potential applications in the field of RSV infections. It can be used as a therapeutic agent for the treatment of RSV infections in high-risk patients, such as infants and older adults. It can also be used as a prophylactic agent to prevent RSV infections in individuals who are at high risk of developing severe symptoms. Furthermore, Foravirumab Biosimilar can also be used in research and development studies to further understand the mechanism of RSV infection and to develop new treatments and vaccines. Its high specificity and ability to activate the immune system make it a valuable tool for studying RSV and its interactions with the host. Conclusion In summary, Foravirumab Biosimilar – Anti-RV mAb – Research Grade is a recombinant humanized monoclonal antibody that specifically targets and neutralizes the respiratory syncytial virus. Its structure, activity, and applications make it a promising therapeutic agent for the treatment and prevention of RSV infections. Its potential to activate the immune system also makes it a valuable tool for research in the field of RSV.